Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults [clinicaltrials:NCT00069030]
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults [clinicaltrials:NCT00069030]
Bio2RDF identifier
NCT00069030
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00069030
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This study will test th ...... ery well tolerated in humans.
brief title [clinicaltrials_vocabulary:brief-title]
Safety of and Immune Response ...... Adjuvant in Uninfected Adults
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2006-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Over 90% of the 40 mill ...... over the course of the study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2003-09-12T00:00:00Z
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
AIDS Vaccines
Adjuvants, Immunologic
Dose-Response Relationship, Immunologic
Drug Administration Schedule
HIV Preventive Vaccine
HIV Seronegativity
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2012-11-07T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00069030
official title [clinicaltrials_vocabulary:official-title]
A Phase I Clinical Trial to Ev ...... VRC-ADJDNA004-IL2-VP (IL-2/Ig)
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
5K08AI051223-03
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2012-11-01T00:00:00Z
identifier
clinicaltrials:NCT00069030
title
Safety of and Immune Response ...... Adjuvant in Uninfected Adults
@en
type
label
Safety of and Immune Response ...... s [clinicaltrials:NCT00069030]
@en